Skip to content

13F-HR filed by Omega Fund Management, LLC

Omega Fund Management, LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-14, with 14 holding rows worth $123,436,833.

Accession
0000950123-24-002504
Filed
2024-02-14
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q4 2023

A holdings report, 14 entries on the cover page, a total value of $123,436,833 stated on the cover page (in dollars after the unit check, H1), rows summing to $123,436,831 with VALUE read as dollars as filed, 13F file number 028-16844. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LEXEO THERAPEUTICS INC52886X107COMMON STOCK2,157,623$28,955,301dollars as filed
REPLIMUNE GROUP INC76029N106COMMON STOCK3,001,319$25,301,119dollars as filed
NUVATION BIO INC COM CL A67080N101Stock15,072,340$22,759,233dollars as filed
ENGENE HOLDINGS INC29286M105COM1,131,175$10,440,745dollars as filed
MORPHIC HLDG INC61775R105COM309,846$8,948,352dollars as filed
SPRUCE BIOSCIENCES INC85209E109COM2,161,022$6,331,794dollars as filed
KRONOS BIO INC50107A104COM3,818,283$4,772,854dollars as filed
IKENA ONCOLOGY INC45175G108COM2,249,123$4,430,772dollars as filed
SANA BIOTECHNOLOGY INC799566104COM843,750$3,442,500dollars as filed
THESEUS PHARMACEUTICALS INC88369M101COM711,479$2,881,490dollars as filed
IMMUNIC INC4525EP101COM1,788,160$2,682,240dollars as filed
SYROS PHARMACEUTICALS INC87184Q206COM NEW251,270$1,957,393dollars as filed
ENGENE HOLDINGS INC29286M113W EXP 10/31/2028475,077$403,815dollars as filed
Senti Biosciences, Inc.81726A100Common Stock195,792$129,223dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0000950123-24-002504this filing2024-02-14acceptance time not in the bulk data set